Washington, DC, August 10, 2009 – AACC announces and audioconference, JUPITER and Beyond: The Future of hsCRP in Assessing CVD Risk, on October 7, 2009 at 2:00pm (Eastern). The audioconference will last 90 minutes.
Heart disease and stroke continue to be the leading causes of death in the U.S. As a result, investigators continue to look for new and emerging biomarkers of disease risk. Recently, measurement of very low concentrations of C-reactive protein (CRP) has gained popularity as an inexpensive means for predicting the risk of cardiovascular disease (CVD). This application has been made possible with the development of high-sensitivity CRP (hsCRP) assays that can measure the typically low concentrations of CRP that may suggest impending cardiac dysfunction. Research over the past 20 years, including the landmark JUPITER (Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin) trial, has prompted interest in the use of CRP blood concentration for predicting a first coronary event, as well as for guiding statin therapy in secondary prevention.
The expert panel of Paul M. Ridker, MD, of Brigham & Women’s Hospital in Boston, MA, and Mary M. Kimberly, PhD, of U.S. Centers for Disease Control & Prevention in Atlanta, GA, will address issues including the utility of hsCRP as a tool for risk assessment in primary CVD prevention, the implications of the JUPITER trial, and the potential role of hsCRP as a tool in secondary CVD prevention and in monitoring statin therapy.
AACC invites interested reporters to participate in this important audioconference at no cost. To register, complete and submit a Press Registration Form. For more information about the event, contact Peter Patterson on either of the above telephone numbers. Information is also available by following the link JUPITER.
This audioconference is supported by Siemens Healthcare Diagnostics.